Artios Pharma entered into a global research collaboration with Novartis for the purpose of discovering and validating next-generation DNA damage response (DDR) targets and enhancing Novartis’ radioligand therapies.
AstraZeneca and Merck’s Combo Therapy Flunks Late-Stage Ovarian Cancer Trial
BRCA mutation, Business, Clinical Trials, Collaborations, Combination Therapies, DNA Damage Response (DDR), National Cancer Institute, NRG Oncology, PARP Inhibitors, Platinum-Sensitive Relapsed Ovarian Cancer, R&D, Vascular Endothelial Growth Factor (VEGF) InhibitorsAstraZeneca and Merck announced that the Phase III GY004 trial of cediranib in combination with Lynparza compared to platinum-based chemotherapy in platinum-sensitive relapsed ovarian cancer failed to meet the primary endpoint.